VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PRQR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PRQRProQR Therapeutics N.V.
$1.15$116M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PRQR logo

ProQR Therapeutics N.V.

PRQR
NASDAQ · Cell & Gene Therapy
$1.15
At close - Nov 17, 4:00 PM EST - USD
Market Cap$121M
P/E-2.7x
52W High$2.49
Volume1.16M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Lumpy Collaboration Revenue Fails to Offset Persistent Cash Burn

ProQR's latest quarter showed revenue of $8.9M, up 133.3% year over year, but this appears driven by irregular licensing or collaboration recognition rather than durable commercial demand, and operating losses of $9.0M persisted regardless.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

PRQR price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-111% Peers

P/E is 111% below peer median

03

Market leadership

RS 23 · Lag

Laggard (Underperforming 77% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 12

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PRQR-42.21%
S&P 500 (^GSPC)+7.21%
1-Year Return
PRQR-43.90%
S&P 500 (^GSPC)+10.03%
3-Year Return
PRQR-21.77%
S&P 500 (^GSPC)+54.84%
5-Year Return
PRQR-84.87%
S&P 500 (^GSPC)+57.36%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$15M-19.2% YoY
Net income FY25
-$41M-45.9% YoY
Free cash flow FY25
-$54M-42.3% YoY
Operating margin FY25
-275.9%-114.7 pts YoY
ROIC (FY25)-
Avg ROIC 5Y-3430.3%
ROE (TTM)-68.4%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (42%)
Revenue Beat Rate4/12 (33%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
-$0.10+11.2%
vs -$0.11
$6M+35.8%
vs $4M
Q3 2026
Aug 13, 2026
-$0.10+23.2%
vs -$0.13
$10M+119.3%
vs $5M
Q2 2026
May 12, 2026
-$0.15+0.0%
vs -$0.15
$2M-54.7%
vs $5M
Q2 2026
Mar 12, 2026
-$0.09-12.5%
vs -$0.08
$6M-16.4%
vs $7M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·6d ago
ProQR Announces Third Quarter 2026 Operating and Financial Results

Fully enrolled Cohorts 1 and 2 of AX-0811 Phase 1 trial; initial target engagement data expected in early January 2027 Full AX-0810 Phase 1 dataset, including Cohort 3 and follow-up data, and new AX-0811 preclinical proof-of-concept data to be presented in December 2026 Multiple clinical milestones expected in H1 of 2027, including initiation of pediatric biliary atresia IIT, initial AX-0422 patient data in MPS I Hurler syndrome, and advancement of AX-2911 into the clinic for MASH IIT Ended Q3 2026 with € 103 million cash and cash equivalents, supporting runway into mid-2028 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

GlobeNewsWire·Oct 28, 2026
ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced upcoming presentations highlighting clinical and preclinical progress with AX-0810 and AX-0811 and the broader Axiomer RNA editing platform at TIDES Europe, The Liver Meeting 2026, Nature Conferences RNA at the Bench and Bedside V.

Defense World·Oct 18, 2026
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Consensus Price Target of $7.60 According to Analysts

ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation

MarketBeat·Oct 2, 2026
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

ProQR Therapeutics NASDAQ: PRQR said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, initially focusing on pediatric biliary atresia.

Filtered for ProQR Therapeutics N.V.More Headlines
04

Compare before deciding

Benchmark PRQR against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for ProQR Therapeutics N.V. (PRQR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PRQR logoPRQRProQR Therapeutics N.V.Current
$1.15$121.11M-2.71-19.18%-228.29%-68.44%—
EDIT logoEDITEditas Medicine, Inc.
$1.83$280.07M-3.8825.39%-144.95%-130.43%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.78$1.1B-3.2216.92%-805.75%-64.73%—
CRSP logoCRSPCRISPR Therapeutics AG
$40.15$3.87B-8.52-89.97%-1812.07%-25.59%—
BEAM logoBEAMBeam Therapeutics Inc.
$20.65$2.12B-20.19120.01%-73.04%-9.69%—
ARWR logoARWRArrowhead Pharmaceuticals, Inc.
$42.99$6.06B-8.41-45.65%-160.64%-172.62%—

Compare PRQR vs Peers

ProQR Therapeutics N.V. (PRQR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EDIT

Most directly comparable listed peer for PRQR.

Scale Benchmark

vs REGN

Larger-name benchmark to compare PRQR against a more recognizable public peer.

Peer Set

Compare Top 5

vs EDIT, NTLA, CRSP, BEAM

Get notified when PRQR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PRQR Frequently Asked Questions

ProQR Therapeutics N.V. (PRQR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is ProQR Therapeutics N.V.'s revenue?

ProQR Therapeutics N.V. (PRQR) reported $18.6M in revenue over the trailing twelve months. Revenue was $15.3M in fiscal year 2025.

How fast is ProQR Therapeutics N.V. growing?

ProQR Therapeutics N.V. (PRQR) grew revenue by 12.7% over the trailing twelve months, compared with the twelve months before.

Is PRQR profitable?

No. ProQR Therapeutics N.V. (PRQR) reported a net loss of $42.4M over the trailing twelve months.

Dividend & Returns
What is PRQR's return on equity?

ProQR Therapeutics N.V. (PRQR) had a return on equity (ROE) of -68.4% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is ProQR Therapeutics N.V.'s free cash flow?

ProQR Therapeutics N.V. (PRQR) had negative free cash flow of $50.3M over the trailing twelve months.

What if you invested $1,000 in PRQR back in 2013?

Total return calculator · dividends reinvested · 13+ years of data

See returns →